Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.
Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Ry AV, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Francica JR, et al. Among authors: tibbitts t. bioRxiv [Preprint]. 2021 Mar 2:2021.03.02.433390. doi: 10.1101/2021.03.02.433390. bioRxiv. 2021. PMID: 33688652 Free PMC article. Preprint.
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Boyoglu-Barnum S, Van De Wetering R, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Van Ry A, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA. Francica JR, et al. Among authors: tibbitts t. Sci Transl Med. 2021 Aug 18;13(607):eabi4547. doi: 10.1126/scitranslmed.abi4547. Epub 2021 Jul 27. Sci Transl Med. 2021. PMID: 34315825 Free PMC article.
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
Berry C, Pavot V, Anosova NG, Kishko M, Li L, Tibbitts T, Raillard A, Gautheron S, Cummings S, Bangari DS, Kar S, Atyeo C, Deng Y, Alter G, Gutzeit C, Koutsoukos M, Chicz RM, Lecouturier V. Berry C, et al. Among authors: tibbitts t. Commun Med (Lond). 2023 May 26;3(1):75. doi: 10.1038/s43856-023-00302-z. Commun Med (Lond). 2023. PMID: 37237062 Free PMC article.
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.
Kalnin KV, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, Anosova NG, Tibbitts T, DiNapoli J, Ulinski G, Piepenhagen P, Cummings SM, Bangari DS, Ryan S, Huang PD, Huleatt J, Vincent D, Fries K, Karve S, Goldman R, Gopani H, Dias A, Tran K, Zacharia M, Gu X, Boeglin L, Abysalh J, Vargas J, Beaulieu A, Shah M, Jeannotte T, Gillis K, Chivukula S, Swearingen R, Landolfi V, Fu TM, DeRosa F, Casimiro D. Kalnin KV, et al. Among authors: tibbitts t. NPJ Vaccines. 2021 Apr 19;6(1):61. doi: 10.1038/s41541-021-00324-5. NPJ Vaccines. 2021. PMID: 33875658 Free PMC article.
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza.
Chivukula S, Plitnik T, Tibbitts T, Karve S, Dias A, Zhang D, Goldman R, Gopani H, Khanmohammed A, Sarode A, Cooper D, Yoon H, Kim Y, Yan Y, Mundle ST, Groppo R, Beauvais A, Zhang J, Anosova NG, Lai C, Li L, Ulinski G, Piepenhagen P, DiNapoli J, Kalnin KV, Landolfi V, Swearingen R, Fu TM, DeRosa F, Casimiro D. Chivukula S, et al. Among authors: tibbitts t. NPJ Vaccines. 2021 Dec 16;6(1):153. doi: 10.1038/s41541-021-00420-6. NPJ Vaccines. 2021. PMID: 34916519 Free PMC article.
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
Kalnin KV, Plitnik T, Kishko M, Huang D, Raillard A, Piolat J, Anosova NG, Tibbitts T, DiNapoli J, Karve S, Goldman R, Gopani H, Dias A, Tran K, Zacharia M, Gu X, Boeglin L, Abysalh J, Vargas J, Beaulieu A, Shah M, Jeannotte T, Gillis K, Chivukula S, Swearingen R, Landolfi V, Fu TM, DeRosa F, Casimiro D. Kalnin KV, et al. Among authors: tibbitts t. Vaccine. 2022 Feb 23;40(9):1289-1298. doi: 10.1016/j.vaccine.2022.01.021. Epub 2022 Jan 31. Vaccine. 2022. PMID: 35101265 Free PMC article.
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H. Kalnin K, et al. Among authors: tibbitts t. Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1. Vaccine. 2017. PMID: 28778613 Free PMC article.
115 results